PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence

American Journal of Nuclear Medicine and Molecular Imaging

Gianfranco Cicoria¹  Ilaria Grassi¹  Filippo Lodi¹  Stefano Fanti¹  Cristina Fonti¹  Luca Toschi¹  Arturo Chiti¹  Sandro Mattioli¹  Egesta Lopci¹  Cristina Nanni¹ 

关键词: Hypoxia;    tumor imaging;    PET;    18F-FDG;    18F-FMISO;    18F-FAZA;    64Cu-ATSM;   

DOI  :  

学科分类：过敏症与临床免疫学

来源: e-Century Publishing Corporation

【 摘 要 】

Hypoxia is a pathological condition arising in living tissues when oxygen supply does not adequately cover the cellular metabolic demand. Detection of this phenomenon in tumors is of the utmost clinical relevance because tumor aggressiveness, metastatic spread, failure to achieve tumor control, increased rate of recurrence, and ultimate poor outcome are all associated with hypoxia. Consequently, in recent decades there has been increasing interest in developing methods for measurement of oxygen levels in tumors. Among the image-based modalities for hypoxia assessment, positron emission tomography (PET) is one of the most extensively investigated based on the various advantages it offers, i.e., broad range of radiopharmaceuticals, good intrinsic resolution, three-dimensional tumor representation, possibility of semiquantification/quantification of the amount of hypoxic tumor burden, overall patient friendliness, and ease of repetition. Compared with the other non-invasive techniques, the biggest advantage of PET imaging is that it offers the highest specificity for detection of hypoxic tissue. Starting with the 2-nitroimidazole family of compounds in the early 1980s, a great number of PET tracers have been developed for the identification of hypoxia in living tissue and solid tumors. This paper provides an overview of the principal PET tracers applied in cancer imaging of hypoxia and discusses in detail their advantages and pitfalls.

【 授权许可】

Unknown